**Highlights of This Issue 2251**

**SMALL MOLECULE THERAPEUTICS**

- **2253** The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

- **2264** Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth

- **2276** Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor
  - Ziyan Y. Pessetto, Yan Ma, Jeff J. Hirst, Margaret von Mehren, Scott J. Weir, and Andrew K. Godwin

- **2288** Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
  - Melissa A. Babcook, Sanjeev Shukla, Pingfu Fu, Edwin J. Vazquez, Michelle A. Puchowicz, Joseph P. Molter, Christine Z. Oak, Gregory T. MacLennan, Chris A. Flask, Daniel J. Lindner, Yvonne Parker, Firouz Daneshgari, and Sanjay Gupta

- **2303** The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
  - Michael D. Arensman, Donatello Telesca, Anna R. Lay, Kathleen M. Kershaw, Nanping Wu, Timothy R. Donahue, and David W. Dawson

- **2315** BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

- **2328** Nanolipolee-007, a Novel Nanoparticle-Based DrugContaining Leelamine for the Treatment of Melanoma
  - Raghavendra Gowda, SubbaRao V. Madhunapantula, Arati Sharma, Omer F. Kuzu, and Gavin P. Robertson

**LARGE MOLECULE THERAPEUTICS**

- **2341** Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
  - Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, and David M. Goldenberg

- **2352** Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
  - Christopher L. Daige, Jason F. Wiggins, Leslie Priddy, Terri Nelligan-Davis, Jane Zhao, and David Brown

**CANCER BIOLOGY AND SIGNAL TRANSDUCTION**

- **2361** Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer

- **2372** Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1
  - Carolina Castillo, M. Luz Flores, Rafael Medina, Begoña Pérez-Valderrama, Francisco Romero, María Tortolero, Miguel A. Japón, and Carmen Sáez

- **2384** Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs
  - Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Steven Grant, Andrew Poklepovic, and Paul Dent

- **2399** Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells
  - Jesiun L. Munoz, Vivian Rodriguez-Cruz, Steven J. Greco, Vipul Nagula, Kathleen W. Scotto, and Pranela Rameshwar
2412 BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine
Rebecca M. Jones, Panagiotis Kotsantis, Grant S. Stewart, Petra Groth, and Eva Petermann

2422 Piperlongumine Chemosensitizes Tumor Cells through Interaction with Cysteine 179 of 1κBα Kinase, Leading to Suppression of NF-κB–Regulated Gene Products
Jia Gang Han, Subash C. Gupta, Sahdeo Prasad, and Bharat B. Aggarwal

2436 Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46

MODELS AND TECHNOLOGIES

2450 An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Jonathan W. Astin, Stephen M. F. Jamieson, Tiffany C.Y. Eng, Maria V. Flores, June P. Misa, Annie Chien, Kathryn E. Crosier, and Philip S. Crosier

2463 Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyung Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, and Sukjoon Yoon

ABOUT THE COVER
Zebrafish embryos can be used to examine mechanisms of vascular development and as a platform with which to identify novel antivascular agents; this is an image of a 2-day-old zebrafish embryo showing developing lymphatic vessels in green (lyve1:egfp) and endothelial cell nuclei in red (kdrl:nls:mcherry). This embryo was live imaged for a further 20 hours to identify novel inhibitors of lymphatic vessel growth and revealed that flunarizine, a calcium channel antagonist, was able specifically induce lymphatic endothelial cell death. For details, see the article by Astin and colleagues on page 2450.
Molecular Cancer Therapeutics

13 (10)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/13/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.